To evaluate the therapeutic index of CDK9 inhibition by NVP-2, we tested the antitumor effects of nontoxic doses of NVP-2 in murine liver cancer models driven by MYC overexpression and Trp53 deletion—the same genetic configuration used in our Cdk9 GEMM studies (Fig. 5A). Here, TP53 is linked to liver cancer.